Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 11, 1998, Pages 3808-3816

  Freda, Pamela U ^a   Post, Kalmon D ^b   Powell, Jeffrey S ^b   Wardlaw, Sharon L ^b  

^a Columbia Coll of Phys and Surgeons ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; BRAIN SURGERY; DISEASE COURSE; FEMALE; GROWTH HORMONE RELEASE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECURRENCE RISK;

EID: 0031763448     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.11.3808     Document Type: Article

References (55)

1. Freda PU, Wardlaw SL, Post KD. 1998 Long term endocrinologie follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg. 89:353-358.
2. Davis DH, Laws ER, Ilstrup DM, et al. 1993 Results of surgical treatment for growth hormone-secreting pituitary adenomas. J Neurosurg. 79:70-75.
3. Fahlbusch R, Honegger J, Schott W, Buchfelder M. 1994 Results of surgery in acromegaly. In: Wass AH, ed. Treating acromegaly 100 years on Bristol. Society of Endocrinology, pp 49-54.
4. Ross DA, Wilson CB. 1998 Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg. 68:854-867.
5. Tindall GT, Oyesiku M, Watts NB, Clark RV, Christy JH, Adams DA. 1993 Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg. 78:205-215.
6. Bates AS, Hoff WV, Jones JM, Clayton RN. 1995 Does treatment of acromegaly affect life expectancy? Metab Clin Exp. 44:1-5.
7. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 41:95-102.
8. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. 1995 Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab. 80:3395-3402.
9. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. 1994 Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab. 78:1312-1319.
10. Hattori N, Shimatsu A, Kato Y, et al. 1990 Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly. J Clin Endocrinol Metab. 70:771-776.
11. Clayton RN. 1997 New developments in the management of acromegaly. Should we achieve absolute biochemical cure? J Endocrinol 155:S23-S29.
12. Lamberts SWJ. 1997 Acromegaly and its treatment. J Endocrinol. 155:S49-S51.
13. Barkan AL, Beitins IZ, Kelch RP. 1988 Plasma insulin-like growth factor-I/ somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 67:69-73.
14. Schatz H, Stracke H, Zapf J. 1983 Diagnostik bei akromegalie. Deutsch Med Wochenschr. 108:1391-1395.
15. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. 1979 Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med. 301:1138-1139.
16. Oppizzi G, Petroncini MM, Dallabonzana D et. al. 1986 Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation. J Clin Endocrinol Metab. 63:1348-1353.
17. Frantz, AG, Rabkin MT. 1964 Human growth hormone. N Engl J Med. 271:1375-1381.
18. Glick SM, Roth J, Yalow RS, Berson SA. 1965 The regulation of growth hormone secretion. Recent Prog Horm Res. 21:241-283.
19. Earll JM, Sparks LL, Forsham PH. 1967 Glucose suppression of serum growth hormone in the diagnosis of acromegaly. JAMA. 201:134-136.
20. Davies RR, Turner S, Johnston DG. 1984 Oral glucose inhibits growth hormone secretion induced by human pancreatic growth hormone releasing factor 1-44 in normal man. Clin Endocrinol (Oxf). 21:477-481.
21. Stewart PM, Smith S, Seth J, Stewart SE, Cole D, Edwards CRW. 1989 Normal growth hormone response to the 75 g oral glucose tolerance test measured by immunoradiometric assay. Ann Clin Biochem. 26:205-206.
22. Masuda A, Shibasaki T, Nakahara M, et al. 1985 The effect of glucose on growth hormone (GH)-releasing hormone-mediated GH secretion in man. J Clin Endocrinol Metab. 60:523-526.
23. Alba-Roth J, Müller OA, Schopohl J, von Werder K. 1988 Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. J Clin Endocrinol Metab. 67:1186-1189.
24. Peñalva A, Burguera B, Casabiell X, Tresguerres JAF, Dieguez C, Casanueva FF. 1989 Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin? Neuroendocrinology. 49:551-554.
25. Balzano S, Loche S, Murtas M, et al. 1989 Potentiation of cholinergic tone counteracts the suppressive effect of oral glucose administration on the GH response to GHRH in man. Horm Metab Res. 21:52-53.
26. Daughaday WH. 1979 New criteria for evaluation of acromegaly. N Engl J Med. 301:1175-1176.
27. Acromegaly Therapy Consensus Development Panel. 1994 Consensus statement: benefits vs. risks of medical therapy for acromegaly. Am J Med. 97:468-472.
28. Jaffe CA, Barkan AL. 1994 Acromegaly: recognition and treatment. Drugs. 47:425-445.
29. Chang-DeMoranville BM, Jackson IMD. 1992 Diagnosis and endocrine testing in acromegaly. Endocrinol Metab Clin North Am. 21:649-668.
30. Celniker AC, Chen AB, Wert RM, Sherman BM. 1989 Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metab. 68:469-476.
31. Reiter EO, Morris AH, MacGillivray MH, Wever D. 1988 Variable estimates of serum growth hormone concentrations by different radioassay systems. J Clin Endocrinol Metab. 66:68-71.
32. Levin PA, Chalew SA, Martin L, Kowarski AA. 1987 Comparison of assays for growth hormone using monoclonal or polyclonal antibodies for diagnosis of growth disorders. J Lab Clin Med. 109:85-88.
33. Baumann G, MacCart J, Arnburn K. 1983 The molecular nature of circulating growth hormone in normal and acromegalic man: evidence for a principal and minor monomeric forms. J Clin Endocrinol Metab. 56:946-952.
34. Baumann G. 1991 Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev. 12:424-449.
35. Ho KKY, Weissberger AJ. 1994 Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol (Oxf). 41:75-83.
36. Jaquet P, Guibout M, Jaquet C et. al. 1980 Orcadian regulation of growth hormone secretion after treatment in acromegaly. J Clin Endocrinol Metab. 50:322-328.
37. Hartman ML, Veldhuis JD, Vance ML, Faria ACS, Furlanetto RW, Thorner MO. 1990 Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab. 70:1375-1384.
38. van den Berg G, Frolich M, Veldhuis JD, Roenfsema F. 1994 Growth hormone secretion in recently operated acromegalic patients. J Clin Endocrinol Metab. 79:1706-1715.
39. Ho PJ, Jaffe CA, Friberg RD, Chandler WF, Barkan AL. 1994 Persistence of rapid growth hormone (GH) pulsatility after successful removal ot GH-producing pituitary tumors. J Clin Endocrinol Metab. 78:1403-1410.
40. Peacey SR, Toogood AA, Shalet SM. 1998 Hypothalamic dysfunction in "cured" acromegaly is treatment modality dependent. J Clin Endocrinol Metab. 83:1682-1686.
41. Arafah BM, Rosenzweig JL, Renstermaker R, Salazar R, McBride CE, Selman W. 1987 Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly. J Lab Clin Med. 109:346-354.
42. Blum WF, Ranke MB. 1990 Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders. Horm Res. 33(Suppl 4):31-37.
43. Jørgensen JOL, Møller N, Møller J, Weeke J, Blum WF. 1994 Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, 2, and -3 in patients with acromegaly before and after adenomectomy. Metabolism. 43:579-583.
44. Grinspoon S, Clemmons D, Swearingen B, Klibanski A. 1995 Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab. 80:927-932.
45. de Herder WW, van der Lely AJ, Janssen JAMJL, Uitterlinden P, Hofland LJ, Lamberts SWJ. 1995 IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. Clin Endocrinol (Oxf). 43:501-505.
46. Thissen JP, Ketelslegers JM, Maiter D. 1996 Use of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults. Growth Regul. 6:222-229.
47. Paramo C, Andrade O MA, Fluiter E, Luna R, de la Fuente J, Garcia-Mayor RV. 1997 Comparative study of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3 level and IGF-I/IGFBP-3 ration measurements and their relationship with an index of clinical activity in the management of patients with acromegaly. Metabolism. 46:494-498.
48. van der Lely AJ, de Herder WW, Janssen JAMJL, Lamberts SWJ. 1997 Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis. J Endocrinol 155:S9-S13.
49. Hartman ML, Veldhuis JD, Thorner MO. 1993 Normal control of growth hormone secretion. Horm Res. 40:37-47.
50. Veldhuis JD, Liem AY, South S, et al. 1995 Differential impact of age, sex steroid hormones and ovesity on basal vs. pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab. 80:3209-3222.
51. Ho KY, Evans WS, Blizzard RM, et al. 1987 Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab. 64:51-58.
52. L'Hermite-Baleriaux M, Copinschi G, Van Cauter E. 1996 Growth hormone assays: early to latest test generations compared. Clin Chem. 42:1789-1795.
53. Maccario M, Procopio M, Grottoli S, et al. 1995 In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose. J Clin Endocrinol Metab. 80:3774-3778.
54. Bonora E, Moghetti P, Zenere M, et al. 1990 Plasma concentrations of growth hormone during hyperglycemic clamp with or without somatostatin infusion in obese subjects. J Clin Endocrinol Metab. 70:1732-1734.
55. Faria ACS, Bekenstein LW, Booth RA, et al. 1992 Pulsatile growth hormone release in normal women during the menstrual cycle. Clin Endocrinol (Oxf). 36:591-596.